These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Hehlmann R; Heimpel H; Kolb HJ; Heinze B; Hochhaus A; Griesshammer M; Pralle H; Queisser WP; Essers U; Falge C Leuk Lymphoma; 1993; 11 Suppl 1():159-68. PubMed ID: 8251890 [TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Hochhaus A; Heinze B Blood; 1994 Dec; 84(12):4064-77. PubMed ID: 7994025 [TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)-Study Group. Hehlmann R; Ansari H; Hasford J; Heimpel H; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Reiter A; Hochhaus A Br J Haematol; 1997 Apr; 97(1):76-85. PubMed ID: 9136944 [TBL] [Abstract][Full Text] [Related]
8. Progress with interferon in CML--results of the MRC UK CML III study. Shepherd PC; Richards SM; Allan NC Bone Marrow Transplant; 1996 May; 17 Suppl 3():S15-8. PubMed ID: 8769693 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Hehlmann R; Heimpel H; Hasford J; Kolb HJ; Pralle H; Hossfeld DK; Queisser W; Löffler H; Heinze B; Georgii A Blood; 1993 Jul; 82(2):398-407. PubMed ID: 8329700 [TBL] [Abstract][Full Text] [Related]
10. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Allan NC; Richards SM; Shepherd PC Lancet; 1995 Jun; 345(8962):1392-7. PubMed ID: 7760609 [TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H; Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239 [TBL] [Abstract][Full Text] [Related]
12. Randomized study on the treatment of chronic myeloid leukemia (CML) in chronic phase with busulfan versus hydroxyurea versus interferon-alpha. Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H Blut; 1988 Feb; 56(2):87-91. PubMed ID: 3277680 [TBL] [Abstract][Full Text] [Related]
13. Emergence of unusual cytogenetic abnormalities under interferon-alpha therapy in patients with chronic myelogenous leukemia. Maloisel F; Uettwiller F; Laplace A; Lioure B; Herbrecht R; Mark M; Dufour P Cancer Genet Cytogenet; 1999 Sep; 113(2):172-6. PubMed ID: 10484986 [TBL] [Abstract][Full Text] [Related]
14. Interferon-alpha and hydroxyurea in early chronic myeloid leukemia: a comparative analysis of the Italian and German chronic myeloid leukemia trials with interferon-alpha. Hasford J; Baccarani M; Hehlmann R; Anseri H; Tura S; Zuffa E Blood; 1996 Jun; 87(12):5384-91. PubMed ID: 8652857 [TBL] [Abstract][Full Text] [Related]
15. [Interferon-alpha in the treatment of chronic myeloid leukemia]. Guilhot F Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394 [No Abstract] [Full Text] [Related]
16. The maintenance of busulphan-induced remissions in chronic granulocytic leukaemia with recombinant interferon alpha-2b. Bergsagel DE; Messner H Br J Cancer; 1990 Jun; 61(6):895-8. PubMed ID: 2372493 [TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy of chronic myelocytic leukemia. Status of the German Multicenter Study on busulfan versus hydroxyurea versus alpha interferon, October 1897]. Hehlmann R; Anger B; Messerer D; Zankovich R; Bergmann L; Kolb HJ; Meyer P; Essers U; Queisser U; Vaupel H Onkologie; 1988 Feb; 11(1):25-9. PubMed ID: 3283622 [TBL] [Abstract][Full Text] [Related]
18. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia]. Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976 [TBL] [Abstract][Full Text] [Related]
19. A prospective comparison of alpha-IFN and conventional chemotherapy in Ph+ chronic myeloid leukemia. Clinical and cytogenetic results at 2 years in 322 patients. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Haematologica; 1992; 77(3):204-14. PubMed ID: 1427426 [TBL] [Abstract][Full Text] [Related]
20. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia. Itoh T; Tamura S; Takemoto Y; Kakishita E Int J Mol Med; 1999 Dec; 4(6):659-63. PubMed ID: 10567680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]